Trials / Unknown
UnknownNCT04792749
Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 77 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to investigate the effects of metformin in addition to the conventional progestin therapy in the fertility-sparing treatment of early stage endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Patients are given 750, 1500, and 2000 mgs of metformin per os daily (dose increases weekly, then maintain at 2000 mgs) in addition to 500 mgs of medroxyprogesterone acetate per os daily and levonorgestrel-releasing intrauterine device for the treatment of early stage endometrial cancer. |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-12-31
- Completion
- 2024-03-31
- First posted
- 2021-03-11
- Last updated
- 2023-04-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04792749. Inclusion in this directory is not an endorsement.